Document is current
Any future updates will be listed below
-
Authors
David, Abel P.
Biswas, Sushobhan
Soltis, Macey P.
Eltawil, Yasmin
Zhou, Ruiqi
Easow, Sarah A.
Cheng, Alan G.
Heller, Stefan
Jan, Taha A. https://orcid.org/0000-0001-8971-7769
-
Funding
Funding for this research was provided by:
National Institute on Deafness and Other Communication Disorders (K08DC019683)
National Institute on Deafness and Other Communication Disorders (T32DC015209)
National Institute on Deafness and Other Communication Disorders (R01DC021110)
National Institute on Deafness and Other Communication Disorders (R01DC020879)
National Institute on Deafness and Other Communication Disorders (R01DC016919)
National Institute on Deafness and Other Communication Disorders (R01DC015201)
National Institute on Deafness and Other Communication Disorders (R21DC022058)
- License Information
-
More Information
Article History
Received: 23 December 2024
Accepted: 23 February 2025
First Online: 13 March 2025
Declarations
:
: S.H. is a paid consultant of Pipeline Therapeutics. T.A.J is a site investigator for Akouos, Inc. for two on-going clinical trials (NCT05572073 and NCT05821959) but does not receive consulting fees or hold stock investments. T.A.J is a consultant for Merck Manuals for book chapter editing. The remaining authors declare no competing interests.
